– FRANCE, Illkirch-Graffenstaden – Syndivia, a research-driven biotechnology company focused on the development of new therapeutic modalities for cancers, today announced that it will benefit from €2m deep tech financing from Bpifrance. Proceeds will be used to further fund the advancement of one company’s drug candidate towards the clinic.
The Deeptech plan was initiated by the French government and has been deployed by Bpifrance since 2019 to support deep tech startups resulting from research based on breakthrough innovations. The main objective is to allow these companies to grow and to stimulate innovation by strengthening the links between academia and the entrepreneurial world.
“We are very grateful to Bpifrance for this generous support. This financing will largely accelerate the development of our lead immunoconjugate for various cancer indications, which to date have a very limited number of effective treatment options,” said Sasha Koniev, CEO.
Alban Stamm, in charge of innovation at Bpifrance, said, “Syndivia, which initially emerged from the research of academic laboratories supported by SATT Conectus and reinforced with iLab 2014 (emergence) and 2015 (development) grants, succeeded in bringing together all the ingredients to meet technological challenges. At Bpifrance, we appreciate Syndivia’s progress to date and especially value the team: initially composed of young researchers with strong entrepreneurial capacity, it surrounded itself with an experienced board bringing together all the key success factors of a biotech startup.”
Bpifrance is the French national investment bank. It finances businesses – at every stage of their development – through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra financial services such as training and consultancy to help entrepreneurs meet their challenges.
For more information: https://www.bpifrance.com
Syndivia is a biotechnology company that is developing a pipeline of targeted therapies for solid cancers by leveraging a specific targeting of the tumor microenvironment and anatomical hallmarks of solid tumors. Syndivia’s mission is to develop new therapies for patients with the most difficult-to-treat cancer indications.
For more information: https://www.syndivia.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.